• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, March 4, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Scientists discover a new promising target for diabetes treatment

Bioengineer by Bioengineer
January 27, 2021
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Helmholtz Zentrum München

Researchers have discovered a novel and druggable insulin inhibitory receptor, named inceptor. The latest study from Helmholtz Zentrum Muenchen, the Technical University of Munich and the German Center for Diabetes Research is a significant milestone for diabetes research as the scientific community celebrates 100 years of insulin and 50 years of insulin receptor discovery. The blocking of inceptor function leads to an increased sensitisation of the insulin signaling pathway in pancreatic beta cells. This might allow protection and regeneration of beta cells for diabetes remission.

Diabetes mellitus is a complex disease characterized by the loss or dysfunction of insulin-producing beta cells in the islets of Langerhans, a specialist “micro-organ” in the pancreas that controls systemic blood sugar levels. Diabetes complications, such as chronic high blood sugar, systemic metabolic failure and, in the long-term, multi-organ damage, create enormous medical and social burdens and leads to premature death. Currently no pharmacological treatment can stop or reverse disease progression. Previous studies have demonstrated that intensive insulin therapy has the potential for improved blood sugar control and diabetes remission but also leads to unintended weight gain and even more severe side effects, such as an increased risk of deep drop in blood sugar causing unawareness.

Heiko Lickert’s* research focuses on the development of regenerative approaches to treat diabetes complementary and alternative to the classical immunological and metabolic therapies. “Insulin resistance in pancreatic beta cells causes diabetes. Therapies that sensitize those cells to insulin may protect patients with diabetes against beta cell loss and failure”, says Lickert. With the discovery of the insulin inhibitory receptor, his research group has found a promising molecular target for beta cell protection and regeneration therapy that does not carry the unintended side effects of intensive insulin therapy.

In experiments with mice, the researchers showed that the function of inceptor is to shield the insulin-producing beta cells from constitutive insulin pathway activation. Remarkably, inceptor is upregulated in diabetes and by blocking insulin signaling it might contribute to insulin resistance.

What happens if the function of inceptor is inhibited genetically or pharmacologically? The group explored this question by knocking out inceptor in beta cells and by blocking its function using monoclonal antibodies. “The result was exactly what we were hoping for: Insulin signaling and the functional beta cell mass was increased. This makes inceptor a very promising target to treat the root cause of diabetes, the loss and dysfunction of beta cells,” says Ansarullah, one of the first-authors of the study published in Nature and diabetes researcher at Helmholtz Zentrum München.

“Frederick Banting noted already in his Nobel Prize lecture for the discovery of the life-saving drug insulin a hundred years ago that ‘Insulin is not a cure for diabetes, but a treatment of the symptoms’. This has not changed in the last century. Our goal for future research is to leverage on the discovery of inceptor and develop drugs for beta cell regeneration. This could be beneficial for patients with type 1 and 2 diabetes and ultimately lead to diabetes remission”, states Lickert.

“A hundred years ago, the discovery of insulin has transformed a deadly illness into a manageable disease. Our discovery of the insulin inhibitory receptor now is another important step to finally get rid of the disease,” says Matthias Tschöp, CEO at Helmholtz Zentrum München. “While the COVID-19 pandemic represents an immediate threat we will overcome, we must not forget that diabetes remains one of the biggest and fastest growing killers on our planet. With a series of recent breakthroughs, now including the discovery of inceptor, our Helmholtz Diabetes Center is doubling down on its mission that is a world without diabetes.”

###

*Heiko Lickert is Director of the Institute of Diabetes and Regeneration Research at Helmholtz Zentrum Muenchen, Professor and Chair of Beta Cell Biology at the Technical University of Munich and member of the German Center for Diabetes Research.

Original publication

Ansarullah et al., 2021: Inceptor counteracts insulin signalling in β-cells to control glycaemia. Nature, DOI: 10.1038/s41586-021-03225-8

Helmholtz Zentrum Muenchen

Helmholtz Zentrum Muenchen is a research center with the mission to discover personalized medical solutions for the prevention and therapy of environmentally-induced diseases and promote a healthier society in a rapidly changing world. It investigates important common diseases which develop from the interaction of lifestyle, environmental factors and personal genetic background, focusing particularly on diabetes mellitus, allergies and chronic lung diseases. Helmholtz Zentrum Muenchen is headquartered in Neuherberg in the north of Munich and has about 2,500 staff members. It is a member of the Helmholtz Association, the largest scientific organization in Germany with more than 40,000 employees at 19 research centers.

Media Contact
Verena Schulz
[email protected]

Original Source

https://www.nature.com/articles/s41586-021-03225-8

Related Journal Article

http://dx.doi.org/10.1038/s41586-021-03225-8

Tags: DiabetesMedicine/HealthMetabolism/Metabolic Diseases
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

Researchers urge greater awareness of delayed skin reactions to Moderna COVID-19 vaccine

March 3, 2021
IMAGE

Mobile app helps young adults talk with friends about risky drug, alcohol use

March 3, 2021

How to track the variants of the pandemic faster

March 3, 2021

Accelerating gains in abdominal fat during menopause tied to heart disease risk

March 3, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    663 shares
    Share 265 Tweet 166
  • People living with HIV face premature heart disease and barriers to care

    83 shares
    Share 33 Tweet 21
  • Global analysis suggests COVID-19 is seasonal

    38 shares
    Share 15 Tweet 10
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    36 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Infectious/Emerging DiseasesTechnology/Engineering/Computer SciencePublic HealthMedicine/HealthBiologyMaterialsClimate ChangeCell BiologyGeneticscancerEcology/EnvironmentChemistry/Physics/Materials Sciences

Recent Posts

  • Gender assumptions harm progress on climate adaption and resilience
  • Researchers urge greater awareness of delayed skin reactions to Moderna COVID-19 vaccine
  • Mobile app helps young adults talk with friends about risky drug, alcohol use
  • MDI Biological Laboratory receives funding to address arsenic threat
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In